ClinicalTrials.Veeva

Menu

Does Weight Loss Surgery and Probiotic Supplementation Lead to a "Lean" Gut Microbiota?

Tufts University logo

Tufts University

Status and phase

Completed
Phase 2
Phase 1

Conditions

Obesity

Treatments

Dietary Supplement: Placebo
Dietary Supplement: Lactobacillus Rhamnosus GG

Study type

Interventional

Funder types

Other

Identifiers

NCT01870544
Tufts Obesity Study

Details and patient eligibility

About

The purpose of the weight-loss study is to characterize the effect of LGG supplementation on the relative abundance of phyla in the gut microbiota of patients undergoing gastric bypass and sleeve gastrectomy surgery, and to elucidate a relationship between the gut microbiota pattern and the degree of weight-loss post-surgery.

The investigators hypothesize that LGG administration will result in a "leaner" pattern of gut microbiota that will lead to higher weight loss at 3 months post-surgery.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age greater than or equal to 18 years
  2. Able to give informed consent and report on side effects
  3. Tolerating an oral/enteral diet
  4. Stable comorbid conditions
  5. Outpatient

Exclusion criteria

  1. Inpatients
  2. Pregnancy (urine test done on all patients routinely pre-op)/ unwilling to comply with contraceptive requirement after gastric bypass surgery
  3. Known use of LGG or another probiotic (not including yogurt) within the previous 30 days
  4. Presence of an active bowel leak, acute abdomen, active intestinal disease, or significant bowel dysfunction
  5. Presence of an absolute neutrophil count less than 500 per cubic mm (must have had a Complete Blood Count within the last 6 months) or anticipation post chemotherapy that the absolute neutrophil count will fall below 500 per cubic mm.
  6. History of adverse reaction to product containing lactobacillus
  7. Active colitis (*see definition below)
  8. Known or suspected allergies to probiotics, lactobacillus, milk protein, or microcrystalline cellulose
  9. Structural heart disease, history of endocarditis or valve replacement, implanted cardiac device, congestive heart failure
  10. Positive baseline stool culture for LGG
  11. Recent or planned chemotherapy or radiation therapy
  12. Solid organ transplant within the prior year
  13. Stem cell transplant within the prior year
  14. On active immunosuppressive medication [anti-rejection, injectable immunosuppressive drugs for autoimmune disease, or corticosteroids (greater than ½ mg per kg body weight of prednisone or its equivalent) not including inhaled or topical steroids]
  15. Allergy or intolerance to or contraindication to two or more of the rescue antibiotic regimens (ampicillin, clindamycin, moxifloxacin)
  16. Participating in another clinical trial
  17. Uncontrolled psychiatric illness

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

18 participants in 2 patient groups, including a placebo group

LGG Administration
Experimental group
Description:
Lactobacillus Rhamnosus GG (LGG) will be taken orally for 44 days. The daily dose is 2\*10\^10 organisms. The LGG is contained in capsules (1\*10\^10 organisms per capsule), and two capsules will be taken per day.
Treatment:
Dietary Supplement: Lactobacillus Rhamnosus GG
Placebo
Placebo Comparator group
Description:
Placebo to be taken orally for 44 days.
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems